|
|
Prepublished online as a Blood First Edition Paper on February 20, 2003; DOI 10.1182/blood-2001-12-0290.
 Previous Article | Table of Contents | Next Article 
Blood, 15 June 2003, Vol. 101, No. 12, pp. 5061-5067
TRANSPLANTATION
Augmentation of umbilical cord blood (UCB) transplantation with ex vivo–expanded UCB cells: results of a phase 1 trial using the AastromReplicell System
Jennifer Jaroscak,
Kristin Goltry,
Alan Smith,
Barbara Waters-Pick,
Paul L. Martin,
Timothy A. Driscoll,
Richard Howrey,
Nelson Chao,
Judy Douville,
Sue Burhop,
Pingfu Fu, and
Joanne Kurtzberg
From the Pediatric and Adult Bone Marrow Transplant Programs at Duke University Medical Center, Durham, NC; Aastrom Biosciences, Ann Arbor, MI; and Rainbow Babies and Childrens Hospital, Cleveland, OH.
Allogeneic stem cell transplantation with umbilical cord blood (UCB) cells is limited by the cell dose a single unit provides recipients. Ex vivo expansion is one strategy to increase the number of cells available for transplantation. Aastrom Biosciences developed an automated continuous perfusion culture device for expansion of hematopoietic stem cells (HSCs). Cells are expanded in media supplemented with fetal bovine serum, horse serum, PIXY321, flt-3 ligand, and erythropoietin. We performed a phase 1 trial augmenting conventional UCB transplants with ex vivo–expanded cells. The 28 patients were enrolled on the trial between October 8, 1997 and September 30, 1998. UCB cells were expanded in the device, then administered as a boost to the conventional graft on posttransplantation day 12. While expansion of total cells and colony-forming units (CFUs) occurred in all cases, the magnitude of expansion varied considerably. The median fold increase was 2.4 (range, 1.0-8.5) in nucleated cells, 82 (range, 4.6-266.4) in CFU granulocyte-macrophages, and 0.5 (range, 0.09-2.45) in CD34+ lineage negative (lin–) cells. CD3+ cells did not expand under these conditions. Clinical-scale ex vivo expansion of UCB is feasible, and the administration of ex vivo–expanded cells is well tolerated. Augmentation of UCB transplants with ex vivo–expanded cells did not alter the time to myeloid, erythroid, or platelet engraftment in 21 evaluable patients. Recipients of ex vivo–expanded cells continue to have durable engraftment with a median follow-up of 47 months (range, 41-51 months). A randomized phase 2 study will determine whether augmenting UCB transplants with ex vivo–expanded UCB cells is beneficial.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Ghiaur, A. Lee, J. Bailey, J. A. Cancelas, Y. Zheng, and D. A. Williams
Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment
Blood,
September 15, 2006;
108(6):
2087 - 2094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Copelan
Hematopoietic stem-cell transplantation.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1813 - 1826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eapen, P. Rubinstein, M.-J. Zhang, B. M. Camitta, C. Stevens, M. S. Cairo, S. M. Davies, J. J. Doyle, J. Kurtzberg, M. A. Pulsipher, et al.
Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months
J. Clin. Oncol.,
January 1, 2006;
24(1):
145 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Lipkin, P. Lenssen, and B. J. Dickson
Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art
Nutr Clin Pract,
August 1, 2005;
20(4):
423 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Ballen
New trends in umbilical cord blood transplantation
Blood,
May 15, 2005;
105(10):
3786 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Chute, G. G. Muramoto, J. Fung, and C. Oxford
Soluble factors elaborated by human brain endothelial cells induce the concomitant expansion of purified human BM CD34+CD38- cells and SCID-repopulating cells
Blood,
January 15, 2005;
105(2):
576 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Laughlin, M. Eapen, P. Rubinstein, J. E. Wagner, M.-J. Zhang, R. E. Champlin, C. Stevens, J. N. Barker, R. P. Gale, H. M. Lazarus, et al.
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia
N. Engl. J. Med.,
November 25, 2004;
351(22):
2265 - 2275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Christopherson II, G. Hangoc, C. R. Mantel, and H. E. Broxmeyer
Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26
Science,
August 13, 2004;
305(5686):
1000 - 1003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gammaitoni, K. C. Weisel, M. Gunetti, K.-D. Wu, S. Bruno, S. Pinelli, A. Bonati, M. Aglietta, M. A. S. Moore, and W. Piacibello
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication
Blood,
June 15, 2004;
103(12):
4440 - 4448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Kim, Y.-J. Chung, T.-G. Kim, Y.-L. Kim, and I.-H. Oh
Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation
Blood,
March 1, 2004;
103(5):
1941 - 1948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Chao, S. G. Emerson, and K. I. Weinberg
Stem Cell Transplantation (Cord Blood Transplants)
Hematology,
January 1, 2004;
2004(1):
354 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
